Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)

04 Apr 2025, 02:50 by Doug Wharley · The Cerbat Gem

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Traders acquired 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the average daily volume of 165 put options.

Wall Street Analyst Weigh In

XENE has been the topic of several research analyst reports. StockNews.com upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 29th. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. Deutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective for the company. Finally, Royal Bank of Canada restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.38.

View Our Latest Stock Report on Xenon Pharmaceuticals

Insider Buying and Selling

In other news, CEO Ian Mortimer sold 22,468 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the sale, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several large investors have recently made changes to their positions in XENE. Erste Asset Management GmbH bought a new position in Xenon Pharmaceuticals during the 3rd quarter valued at about $1,932,000. HighVista Strategies LLC raised its stake in shares of Xenon Pharmaceuticals by 1.4% in the third quarter. HighVista Strategies LLC now owns 73,762 shares of the biopharmaceutical company’s stock valued at $2,904,000 after acquiring an additional 1,047 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Xenon Pharmaceuticals by 144.2% in the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock valued at $100,506,000 after acquiring an additional 1,507,135 shares during the last quarter. State Street Corp boosted its holdings in shares of Xenon Pharmaceuticals by 13.2% in the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company’s stock worth $11,004,000 after acquiring an additional 32,701 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in Xenon Pharmaceuticals by 31.0% during the 3rd quarter. Two Sigma Advisers LP now owns 273,700 shares of the biopharmaceutical company’s stock worth $10,776,000 after acquiring an additional 64,800 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Down 2.4 %

NASDAQ XENE opened at $30.71 on Friday. Xenon Pharmaceuticals has a 1-year low of $30.07 and a 1-year high of $46.00. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -10.89 and a beta of 1.21. The stock’s 50 day moving average is $37.11 and its two-hundred day moving average is $39.51.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.05. On average, analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Xenon Pharmaceuticals Company Profile

(Get Free Report)